Abstract
Sjogren’s syndrome (SS) is a chronic inflammatory disease characterized by salivary and lacrimal gland dysfunction although extraglandular manifestations are also found. Suitable study models and in vitro cell culture designs are used to approach SS pathogenic mechanisms. Cellular and molecular pathways involved in gland homeostasis loss and the autoimmune response are focused in the search of novel drug targets and biomarkers. Vasoactive intestinal peptide (VIP) has trophic, pro-secretory and immunomodulatory effects in several chronic and autoimmune disease models. Here we review evidence pointing to its role as an endogenous modulator of gland homeostasis at early stages of the disease. Particularly, mechanisms involving VIP/VPAC system in the course of salivary function impairment in the non obese diabetic (NOD) mouse model of Sjögren’s syndrome are described.
Keywords: Vasoactive intestinal peptide – Sjogren Syndrome – Salivary epithelial cells.
Current Pharmaceutical Design
Title:Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function
Volume: 20 Issue: 29
Author(s): Hauk Vanesa, Calafat Mario, Grasso Esteban, Fraccaroli Laura, Paparini Daniel, Ramhorst Rosanna and Perez Leiros Claudia
Affiliation:
Keywords: Vasoactive intestinal peptide – Sjogren Syndrome – Salivary epithelial cells.
Abstract: Sjogren’s syndrome (SS) is a chronic inflammatory disease characterized by salivary and lacrimal gland dysfunction although extraglandular manifestations are also found. Suitable study models and in vitro cell culture designs are used to approach SS pathogenic mechanisms. Cellular and molecular pathways involved in gland homeostasis loss and the autoimmune response are focused in the search of novel drug targets and biomarkers. Vasoactive intestinal peptide (VIP) has trophic, pro-secretory and immunomodulatory effects in several chronic and autoimmune disease models. Here we review evidence pointing to its role as an endogenous modulator of gland homeostasis at early stages of the disease. Particularly, mechanisms involving VIP/VPAC system in the course of salivary function impairment in the non obese diabetic (NOD) mouse model of Sjögren’s syndrome are described.
Export Options
About this article
Cite this article as:
Vanesa Hauk, Mario Calafat, Esteban Grasso, Laura Fraccaroli, Daniel Paparini, Rosanna Ramhorst and Claudia Leiros Perez, Neuroimmune Aspects of Sjogren`s Syndrome: Role of VIP/VPAC System in Immune and Salivary Gland Epithelial Cell Function, Current Pharmaceutical Design 2014; 20 (29) . https://dx.doi.org/10.2174/1381612820666140130203636
DOI https://dx.doi.org/10.2174/1381612820666140130203636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroprotection by Association of Palmitoylethanolamide with Luteolin in Experimental Alzheimer’s Disease Models: The Control of Neuroinflammation
CNS & Neurological Disorders - Drug Targets Superparamagnetic Magnetite (Fe3O4) Nanoparticles for Bio-Applications
Recent Patents on Materials Science Impact of Cytokines and Chemokines on Alzheimer’s Disease Neuropathological Hallmarks
Current Alzheimer Research Ceramide in Chemotherapy of Tumors
Recent Patents on Anti-Cancer Drug Discovery Bioactive N-Phenylimidazole Derivatives
Current Chemical Biology A Closer Look to Polyesters: Properties, Synthesis, Characterization, and Particle Drug Delivery Applications
Nanoscience & Nanotechnology-Asia Receptor Tryosine Kinase Inhibitors as Potent Weapons in War Against Cancers
Current Pharmaceutical Design Delineating Characteristic Sequence and Structural Features of Precursor and Mature Piwi-interacting RNAs of Epithelial Ovarian Cancer
Current Bioinformatics Neurodegenerative Disorders and the Current State, Pathophysiology, and Management of Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Is the Modulation of Autophagy the Future in the Treatment of Neurodegenerative Diseases?
Current Topics in Medicinal Chemistry Prolyl Oligopeptidase: A Rising Star on the Stage of Neuroinflammation Research
CNS & Neurological Disorders - Drug Targets Novel In Situ Activity Assays for the Quantitative Molecular Analysis of Neurodegenerative Processes in the Retina
Current Medicinal Chemistry Adrenoceptors: Non Conventional Target for Breast Cancer?
Current Medicinal Chemistry The Role of the PACAP Signaling System in Depression
Current Pharmaceutical Design Polysulfated/Sulfonated Compounds for the Development of Drugs at the Crossroad of Viral Infection and Oncogenesis
Current Pharmaceutical Design NPY Signalling Pathway in Bone Homeostasis: Y1 Receptor as a Potential Drug Target
Current Drug Targets Pharmacological Modulation of p53 Function in Cancer Therapy
Current Signal Transduction Therapy Targeting Apoptosis Resistance in Rhabdomyosarcoma
Current Cancer Drug Targets Biological Properties of Baicalein in Cardiovascular System
Current Drug Targets - Cardiovascular & Hematological Disorders Potential Therapeutic Effects of Oleuropein Aglycone in Alzheimer's Disease
Current Pharmaceutical Biotechnology